What is Lifesci Capital’s Estimate for DBVT FY2026 Earnings?

DBV Technologies S.A. (NASDAQ:DBVT) – Analysts at Lifesci Capital decreased their FY2026 earnings per share estimates for DBV Technologies in a research report issued on Wednesday, December 17th. Lifesci Capital analyst S. Slutsky now forecasts that the company will post earnings per share of ($1.95) for the year, down from their prior forecast of ($1.65). The consensus estimate for DBV Technologies’ current full-year earnings is ($7.05) per share.

A number of other equities analysts also recently issued reports on the stock. HC Wainwright set a $40.00 price objective on shares of DBV Technologies in a report on Thursday. Weiss Ratings reissued a “sell (d-)” rating on shares of DBV Technologies in a research report on Monday, December 8th. Guggenheim restated a “buy” rating and set a $51.00 price target (up from $35.00) on shares of DBV Technologies in a report on Wednesday. Zacks Research upgraded shares of DBV Technologies from a “strong sell” rating to a “hold” rating in a research note on Monday, September 29th. Finally, Wall Street Zen upgraded DBV Technologies from a “sell” rating to a “hold” rating in a research note on Friday, November 28th. Two analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating, one has given a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $35.38.

DBV Technologies Trading Down 4.6%

Shares of DBV Technologies stock opened at $21.52 on Friday. The company has a market capitalization of $864.24 million, a P/E ratio of -4.16 and a beta of -1.10. The stock has a fifty day simple moving average of $15.23 and a 200 day simple moving average of $11.72. DBV Technologies has a 12-month low of $2.74 and a 12-month high of $26.18.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in DBVT. New York State Common Retirement Fund purchased a new stake in shares of DBV Technologies during the 3rd quarter worth approximately $34,000. Two Sigma Investments LP purchased a new position in DBV Technologies in the third quarter valued at approximately $167,000. Citadel Advisors LLC bought a new position in DBV Technologies during the third quarter valued at $220,000. DLD Asset Management LP purchased a new stake in DBV Technologies in the third quarter worth $250,000. Finally, Nan Fung Trinity HK Ltd. bought a new stake in shares of DBV Technologies in the second quarter valued at $340,000. 71.74% of the stock is currently owned by hedge funds and other institutional investors.

DBV Technologies Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.